ABOS (Acumen Pharmaceuticals) Book Value per Share: $1.21 (As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.59
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals Book Value per Share?

Acumen Pharmaceuticals ABOS -3.00% 34 Book Value per Share is $1.21 as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acumen Pharmaceuticals's book value per share for the quarter that ended in Mar. 2026 was $1.21.

During the past 12 months, Acumen Pharmaceuticals's average Book Value Per Share Growth Rate was -52.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -36.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Acumen Pharmaceuticals was -18.40% per year. The lowest was -36.80% per year. And the median was -27.60% per year.

Acumen Pharmaceuticals's current price is $2.59. Its book value per share for the quarter that ended in Mar. 2026 was $1.21. Hence, today's PB Ratio of Acumen Pharmaceuticals is 2.14.

During the past 7 years, the highest P/B Ratio of Acumen Pharmaceuticals was 2.21. The lowest was 0.00. And the median was 0.00.

Acumen Pharmaceuticals  (NAS:ABOS) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Acumen Pharmaceuticals Book Value per Share Related Terms

Acumen Pharmaceuticals Book Value per Share Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals Book Value per Share Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial 5.56 4.60 4.61 3.03 1.16

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 1.93 1.54 1.16 1.21

ABOS vs YDES, PYXS, CRBU: Book Value per Share Comparison

For the Biotechnology subindustry, Acumen Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's PB Ratio falls into.


ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals Book Value per Share Calculation

Acumen Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(70.43-0.00)/60.58
=1.16

Acumen Pharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(87.48-0.00)/72.23
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $1.21 mean?
Acumen Pharmaceuticals (ABOS) has a Book Value per Share of $1.21 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' Book Value per Share too high?
Acumen Pharmaceuticals' current Book Value per Share is $1.21. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Book Value per Share compare to YDES and PYXS?
Acumen Pharmaceuticals' Book Value per Share of $1.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current Book Value per Share is $1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Book Value per Share of $1.21. The current Book Value per Share is $1.21. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Book Value per Share is $1.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price